File photo

Alex­is Borisy has $200M to back a mar­ket-based plan aimed at cur­ing Amer­i­ca’s drug pric­ing ‘sick­ness’

SAN FRAN­CIS­CO — As a high-pro­file fig­ure in the biotech boom that has trans­formed the in­dus­try over the last decade, Alex­is Borisy co-found­ed a slew of star­tups. One of those com­pa­nies is Blue­print Med­i­cines, where he has been on the board since 2011.

A few days ago, Borisy’s biotech reached a mile­stone every up­start yearns for. The FDA ap­proved their first pre­ci­sion can­cer med­i­cine — and the ex­ec­u­tive team im­me­di­ate­ly priced it in the US at a stag­ger­ing $32,000 a month, al­most twice what some an­a­lysts had ex­pect­ed. If it per­forms ac­cord­ing to the US mod­el, that’s far more than any oth­er pay­er will cov­er in the rest of the world — even af­ter any ne­go­ti­at­ed dis­count. And that’s just the lat­est in a long line­up of new drugs from com­pa­nies big and small bid­ding up ever-high­er price tags.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.